Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mina Therapeutics Appoints Chief Scientific Officer

This article was originally published in Scrip

Executive Summary

Mina Therapeutics has appointed David Blakey chief scientific officer. Blakey joins the company from AstraZeneca where he held various roles in research and development over 28 years. Most recently, Blakey was chief scientific in oncology and before this he led the company's first collaboration in therapeutic antibodies with Abgenix.

Advertisement

Related Content

MiNA Pursuing The Other Side Of RNA Interference With Small Activating RNA Approach

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel